LEAP THERAPEUTICS, INC. (LPTX) financial statements (2021 and earlier)

Company profile

Business Address 47 THORNDIKE STREET
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments5241626
Cash and cash equivalents5241626
Business combination, contingent consideration, asset00  
Other undisclosed current assets0012
Total current assets:5241728
Noncurrent Assets
Operating lease, right-of-use asset1 
Property, plant and equipment0000
Deposits noncurrent assets11  
Deferred income tax assets0 
Other noncurrent assets  21
Deferred tax assets, net00
Other undisclosed noncurrent assets02  
Total noncurrent assets:2321
TOTAL ASSETS:5471929
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5866
Accounts payable3543
Accrued liabilities3333
Deferred revenue2 
Debt0   
Other undisclosed current liabilities 0  
Total current liabilities:7866
Noncurrent Liabilities
Long-term debt and lease obligation0   
Operating lease, liability0 
Liabilities, other than long-term debt00  
Financial instruments subject to mandatory redemption, settlement terms, share value, amount00  
Other undisclosed noncurrent liabilities 1312
Total noncurrent liabilities:01312
Total liabilities:891018
Stockholders' equity
Stockholders' equity attributable to parent47(2)911
Common stock0000
Additional paid in capital270193162142
Accumulated other comprehensive income (loss)(1)00(0)
Accumulated deficit(223)(195)(154)(130)
Total stockholders' equity:47(2)911
TOTAL LIABILITIES AND EQUITY:5471929

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Gross profit:2   
Operating expenses(30)(33)(31)(32)
Operating loss:(29)(33)(31)(32)
Nonoperating income (expense)10(1)1
Foreign currency transaction gain (loss), before tax10(1)1
Interest and debt expense(0)(0)(0)(0)
Loss from continuing operations before equity method investments, income taxes:(28)(33)(32)(32)
Other undisclosed income from continuing operations before income taxes0082
Loss from continuing operations before income taxes:(28)(33)(23)(30)
Income tax expense (benefit)00(0)0
Net loss attributable to parent:(28)(33)(23)(30)
Preferred stock dividends and other adjustments(1)(0) (0)
Other undisclosed net loss available to common stockholders, basic(9)   
Net loss available to common stockholders, basic:(38)(33)(23)(30)
Other undisclosed net loss available to common stockholders, diluted  (7)(0)
Net loss available to common stockholders, diluted:(38)(33)(30)(30)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(28)(33)(23)(30)
Comprehensive loss:(28)(33)(23)(30)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(1)(0)1(1)
Comprehensive loss, net of tax, attributable to parent:(28)(33)(23)(30)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: